RELAPSED /REFRACTORY DLBCL
Clinical trials for RELAPSED /REFRACTORY DLBCL explained in plain language.
Never miss a new study
Get alerted when new RELAPSED /REFRACTORY DLBCL trials appear
Sign up with your email to follow new studies for RELAPSED /REFRACTORY DLBCL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Double immune attack: new combo therapy targets tough lymphoma
Disease control Not yet recruitingThis phase 2 trial tests a new treatment strategy for people with a fast-growing blood cancer (large B-cell lymphoma) that has come back or not responded to standard therapy. The approach uses two immune-based treatments: a drug called glofitamab given before and after standard C…
Matched conditions: RELAPSED /REFRACTORY DLBCL
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
Radiation and immunotherapy team up against hard-to-treat lymphoma
Disease control Not yet recruitingThis study tests whether giving radiation therapy before the immunotherapy drugs obinutuzumab and glofitamab can improve outcomes for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). About 40 adults who have already tried at least two prior treatments wil…
Matched conditions: RELAPSED /REFRACTORY DLBCL
Phase: PHASE2 • Sponsor: Olivia Newton-John Cancer Research Institute • Aim: Disease control
Last updated Jun 12, 2026 12:08 UTC